TriSalus Life Sciences (NASDAQ:TLSI) Director Acquires 50,000 Shares of Company Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) Director Mats Wahlstrom bought 50,000 shares of the business’s stock in a transaction on Thursday, November 12th. The stock was bought at an average cost of $2.24 per share, with a total value of $112,000.00. Following the completion of the purchase, the director directly owned 197,555 shares in the company, valued at approximately $442,523.20. The trade was a 33.89% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

TriSalus Life Sciences Stock Performance

Shares of TLSI stock opened at $2.43 on Monday. The company has a current ratio of 4.22, a quick ratio of 3.86 and a debt-to-equity ratio of 47.60. TriSalus Life Sciences, Inc. has a twelve month low of $2.20 and a twelve month high of $7.95. The company’s 50-day moving average price is $4.05 and its 200-day moving average price is $4.29. The stock has a market cap of $149.63 million, a price-to-earnings ratio of -4.96 and a beta of 0.50.

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $12.88 million for the quarter, compared to the consensus estimate of $14.02 million. As a group, equities analysts predict that TriSalus Life Sciences, Inc. will post -0.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

TLSI has been the topic of several research analyst reports. Guggenheim set a $12.00 price objective on shares of TriSalus Life Sciences in a report on Wednesday, September 23rd. Canaccord Genuity Group cut their target price on TriSalus Life Sciences from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, November 10th. Stifel Nicolaus set a $12.00 price target on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Zacks Research raised TriSalus Life Sciences to a “hold” rating in a research note on Thursday, September 10th. Finally, Wall Street Zen downgraded TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, TriSalus Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.20.

View Our Latest Research Report on TLSI

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors have recently modified their holdings of the company. Cura Wealth Advisors LLC acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter worth about $36,000. Russell Investments Group Ltd. acquired a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth about $68,000. Provenance Wealth Advisors LLC purchased a new stake in TriSalus Life Sciences during the third quarter worth approximately $94,000. Renaissance Technologies LLC purchased a new stake in TriSalus Life Sciences during the first quarter worth approximately $124,000. Finally, Deutsche Bank AG acquired a new position in TriSalus Life Sciences in the second quarter valued at approximately $221,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.

Read More

Insider Buying and Selling by Quarter for TriSalus Life Sciences (NASDAQ:TLSI)

Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.